Title
Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)
A Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of Intravenous NKTT120 in Adults With Stable Sickle Cell Disease
Phase
Phase 1Lead Sponsor
NKT TherapeuticsStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Sickle Cell DiseaseIntervention/Treatment
nktt120 ...Study Participants
21The purpose of this study is to determine the safety, pharmacokinetics, and pharmacodynamics of NKTT120 in adult patients with stable sickle cell disease.
Inclusion Criteria: Age 18 to 50 years Subject has a confirmed diagnosis of HbSS or HbSβ0thal Subject has stable SCD defined as not having acute VOC, ACS, or other major SCD associated event during the month prior to enrollment Exclusion Criteria: Subject had an SCD-related VOC or ACS that required hospitalization or treatment in acute care outpatient setting in the month prior to enrollment Subject requires a program of prescheduled regularly administered packed red blood cell (pRBC) transfusions or Subject received a pRBC transfusion in the month prior to enrollment Subject has evidence of latent or active tuberculosis Subject has a major concurrent illness or medical condition Subject is pregnant or nursing
